Study of alpibectir plus ethionamide for TB meningitis
Treatments studied
Part of Brain & nervous system, Infections clinical trials.
This trial tests a new combination of drugs (alpibectir plus ethionamide) for people with tuberculosis meningitis (TB meningitis), a serious infection of the brain and spinal cord lining. It aims to see if the combination works better than standard treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 15 and 64 years old.
- You have been diagnosed with definite or probable TB meningitis (using specific criteria).
- You or your family member can give informed consent (or your doctor can get consent later when you are better).
- You have not already received more than 14 days of standard TB treatment (HRZE).
- You are not allergic or resistant to the study drugs.
- You do not have severe liver or kidney problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental oral TB drug called alpibectir given together with ethionamide for people with newly diagnosed lung TB. The goal is to see how well the combination works and if it is safe.
This trial tests if giving a stronger combination of TB drugs for meningitis can save more lives. It's for patients who have been diagnosed with tuberculosis meningitis and have not yet started more than 5 days of TB treatment.
This trial tests an intensified, shorter treatment plan for TB meningitis (TB in the lining around the brain) in adults, including people with HIV. It may help some patients get better with a structured plan while researchers compare treatment outcomes and safety.
This Phase 2 study tests treatment for people with newly diagnosed, drug-susceptible pulmonary (lung) tuberculosis (TB). It aims to see whether the study treatment works well and is safe for curing TB.
This study is testing new combinations of drugs to treat tuberculosis (TB) in the lungs. It aims to find a more effective and shorter treatment, and you may benefit from receiving these new drugs while helping advance TB research.
This Phase 2 trial studies whether a TNF-blocking medicine can lower the risk of death in people with HIV who also have TB meningitis. You would receive standard TB meningitis treatment plus the study drug, if you meet the criteria.
Hear when a new Tuberculosis Meningitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.